Archive · 2026 · October 2026

Daily digest — 2026-10-16

2026-10-16

Eight science items today: a BCL6 PROTAC, a brain-penetrant MTA-cooperative PRMT5 inhibitor, BAX inhibitors, oral SLC6A19 inhibitors, a probe-validity check on Elevenostat, a NaV1.7 probe, Tau-LRP1 screening hits and covalent mitotic inhibitors. Five business items: Roche–Rona, Zealand–Generate, Gilead–Vir, Pfizer–Enodia and Verastem's KRAS G12D data.

⚗️

Medicinal Chemistry

8 articles

High-content screen of a covalent library finds new early mitotic inhibitors

  • A cell-based high-content imaging screen was built to catch early mitotic spindle assembly defects.
  • Run against a 3,520-compound cysteine-reactive library, it found a microtubule depolymerizer, a spindle-positioning disruptor and compounds that disturb spindle structure and chromosome alignment.
  • Two hits caused mitotic arrest and reduced cancer cell viability (preprint; not yet peer reviewed).
💡 Points

Phenotypic screening with a covalent library is a sensible way to find chemotypes that target-based approaches would never pick. The weak point is deconvolution: until the cysteine targets are identified, a microtubule depolymerizer risks being one more tubulin binder. Worth tracking for the non-tubulin hits.

Identification of Cysteine-Reactive Early Mitotic Inhibitors ↗

Elevenostat is a multi-HDAC inhibitor biased to HDAC6, not an HDAC11-selective probe

  • Re-testing Elevenostat (JB3-22) against recombinant HDAC isoforms with two orthogonal HDAC11 assays showed only weak HDAC11 inhibition.
  • Full HDAC1–11 profiling found much stronger inhibition of HDAC6 and HDAC10, plus class I enzymes, with HDAC11 the least sensitive isoform.
  • Cellular readouts (tubulin and histone acetylation, reduced viability) matched HDAC6 and class I engagement, so past HDAC11 conclusions drawn from this compound need re-reading.
💡 Points

This is the unglamorous but valuable kind of paper: a compound used as an HDAC11 tool turns out to hit HDAC6 hardest. Any phenotype published with Elevenostat now has an attribution problem. Before I reuse an inhibitor as a probe, I want full-panel selectivity and a matched inactive control, which this case argues for.

Elevenostat Is an HDAC6/Class I-Biased Multi-HDAC Inhibitor Rather than an HDAC11-Selective Chemical Probe ↗

Aminopyrimidine NaV1.7 probe inhibits resting and inactivated states almost equally

  • An automated patch-clamp screening cascade, built to deprioritize classic local-anesthetic pore binders, yielded an aminopyrimidine hit that was optimized into compound 6.
  • Compound 6 combined balanced resting- and inactivated-state potency, selectivity over NaV1.5 and a tetrodotoxin-like isoform profile that includes NaV1.1.
  • SAR pointed to the aminopyrimidine core and a methylene-linked aniline as key determinants of this profile.
💡 Points

State dependence is a leading suspect for why NaV1.7 programs keep failing clinically, so a probe that blocks resting and inactivated states alike is a good way to test that hypothesis. NaV1.1 activity is a flag for seizure-related liability, and I'd want a binding-site assignment before reading too much into the profile.

A Nontoxin Aminopyrimidine Probe for Near State-Independent Na V 1.7 Inhibition ↗

Turning EGFR kinase inhibitors into BAX inhibitors with the kinase activity engineered out

  • A virtual screen flagged EGFR inhibitors, including dacomitinib and gefitinib-like cores, as possible BAX binders.
  • Systematic modification built a first SAR for BAX inhibition and reduced EGFR kinase activity considerably.
  • The series showed better BAX inhibition in vitro, in cells and in iPSC-derived brain organoids, with drug-like properties.
💡 Points

Inhibiting an executioner protein like BAX is hard, so starting from a privileged kinase scaffold is pragmatic. The real test is whether the EGFR activity is gone enough: a cytoprotectant that still hits kinases is a poor neuroprotective. I'd like orthogonal proof of direct BAX engagement and a broader kinome panel.

Discovery of Anti-apoptotic BAX Inhibitors ↗

Scaffold-hopped BCL6 PROTAC degrades its target in DLBCL cells and works orally in xenografts

  • Scaffold hopping from the BCL6 ligand BI-3802 gave a new tricyclic oxazinoquinolinone binder.
  • Linker and CRBN-recruiter tuning produced compound 15, a PROTAC that degraded BCL6 quickly and potently, in a CRBN- and proteasome-dependent way.
  • It strongly suppressed BCL6-dependent DLBCL cell growth, and oral dosing inhibited tumor growth in an OCI-LY1 xenograft without evident toxicity.
💡 Points

BI-3802 is a polymerizing degrader with a peculiar mechanism, so a conventional CRBN-recruiting PROTAC from a fresh tricyclic core is a useful alternative route to BCL6 removal. Oral efficacy matters most here; I'd want to see how the molecule balances size and permeability, and whether degradation depth tracks with tumor response across non-OCI-LY1 lines.

Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma ↗

GTA182: a brain-penetrant MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors

  • Structure-based design and multiparameter optimization gave GTA182, a tricyclic amide with strong selectivity for MTAP-deleted over wild-type cells.
  • Low efflux and tuned physicochemical properties delivered unbound brain exposure in the efficacious range.
  • Orally dosed, it caused regression in MTAP-deleted xenografts and an orthotopic glioblastoma model, and early Phase I data reported good tolerability and intracranial tumor shrinkage.
💡 Points

MTA-cooperative PRMT5 inhibitors are crowded, and brain exposure is the clear differentiator: MTAP deletion is common in glioblastoma, where most competitors can't reach the tumor. A clinical readout appearing in a medicinal chemistry paper is rare. I'd now look at hematologic safety, the usual liability for this class, and at how much of the intracranial effect is truly unbound-drug driven.

Discovery of GTA182, a Novel CNS-Active Tricyclic Amide MTA-Cooperative PRMT5 Inhibitor for MTAP -Deleted Cancers ↗

Cryo-EM-guided pocket merging yields an oral allosteric SLC6A19 inhibitor

  • Virtual screening against the allosteric pocket seen in the SLC6A19/cinromide cryo-EM structure gave a starting hit.
  • A second, partially overlapping pocket from a further cryo-EM structure inspired merged analogues, leading to a potent, selective, orally bioavailable compound 20.
  • Compound 20 was weaker on mouse than on non-human primate SLC6A19, yet oral dosing raised urinary amino acid excretion dose-dependently.
💡 Points

Membrane transporters rarely give such a clean example of structure-driven design: two cryo-EM pockets, one merged series, in vivo pharmacodynamics from a simple urinary readout. The mouse potency shift is the practical snag for efficacy models, so the primate retention is reassuring. Next I'd want to know the margin for amino acid depletion.

Structure-Guided Discovery of Orally Bioavailable Allosteric SLC6A19 Inhibitors that Promote Urinary Amino Acid Excretion In Vivo ↗

HTS framework finds small molecules that block tau binding to the LRP1 receptor

  • The team built a quantitative assay set around purified LRP1 ligand-binding domain 4, using fluorescence polarization, split luciferase and TR-FRET.
  • Tau, RAP and a peptide ligand competed for overlapping binding sites with nanomolar-range affinities across formats.
  • A screen on this platform identified small-molecule inhibitors of the interaction, a starting point against tau uptake and spread.
💡 Points

Protein–protein interactions with a receptor ectodomain are tough targets, so three orthogonal assays is the right way to weed out artifacts. I'd treat the hits cautiously until they show activity in cellular tau-uptake assays and clear LRP1's many other ligands, such as ApoE and RAP, without broad liabilities.

High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction ↗

🏢

Industry News

5 articles

Verastem reports encouraging early data for its oral KRAS G12D inhibitor in pancreatic cancer

  • Verastem presented early results for its KRAS G12D inhibitor, studied in more than 200 patients with advanced solid tumors including metastatic pancreatic cancer and others.
  • Other coverage describes anti-tumor activity and a manageable safety profile across pancreatic, colorectal and lung cancers.
  • This summary rests on the public lead of a paywalled STAT piece plus secondary reports, so details are limited.
💡 Points

KRAS G12D in pancreatic cancer is the biggest open space after G12C, and early activity with clean liver safety is what the field needs to see. The competitive question is durability against other G12D programs, including those from large players. Registration-directed Phase 2 trials and Fast Track status give Verastem a credible path, but single-arm early data can flatter.

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer ↗

Gilead licenses three dual-masked T-cell engagers from Vir in a deal worth up to about $1.9B

  • Vir will discover, design and optimize three T-cell engagers against solid-tumor antigens on its dual-masked PRO-XTEN platform; Gilead holds exclusive rights to nominate candidates and then develops and commercializes them.
  • Vir receives $90M up front ($65M cash plus a $25M equity investment) and $45M in near-term preclinical milestones.
  • Up to $1.74B in development, regulatory and commercial milestones and tiered royalties could follow.
💡 Points

This is Gilead's third T-cell engager move in a short stretch (Merus, Ouro, now Vir), so the oncology thesis is clearly masked, conditional-activation TCEs for solid tumors. For Vir, it's the second platform deal this year and non-dilutive cash that lets it fund its own pipeline; the equity premium shows Gilead's commitment. Preclinical risk stays high.

Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs ↗

Zealand pays $30M upfront for Generate's AI-designed multispecific proteins in obesity

  • Generate will use its AI platform to design multispecific proteins for obesity and metabolic disease, leading research to lead-candidate selection.
  • Zealand then takes over clinical development, regulatory work and commercialization, starting with two programs and an option on a third.
  • Reported terms: $30M upfront, up to $35M of early preclinical milestones and nearly $1.2B in total milestones plus tiered royalties.
💡 Points

Zealand already has Roche and Boehringer on its obesity assets, and this adds a third modality bet, AI-designed biologics, with a small upfront. The structure keeps risk on Generate until a lead exists. For Generate, it's another big-pharma-style validation after Novartis and Amgen, although multispecifics in obesity are still unproven clinically.

Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline ↗

Pfizer partners with Enodia on Sec61 inhibitors in a deal worth over $500M

  • Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work.
  • The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top.
  • It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.
💡 Points

Sec61 is a hard target: it is a core translocon, and the chemistry has to block only disease-linked proteins without general toxicity. Two big pharmas moving within a week suggests selectivity data are persuasive behind closed doors, but the undisclosed upfront and targets mean the real signal is still thin. Watch which client proteins each company is going after.

Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field ↗

Roche licenses Rona's ALK7-targeting RNAi obesity candidate in a deal worth up to $1.16B

  • Roche gets an exclusive license to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity.
  • Terms: up to $100M in upfront and near-term milestones, plus up to $1.06B in longer-term milestones and tiered royalties.
  • The program's codename and development stage were not disclosed.
💡 Points

ALK7 is the second hot RNAi obesity target after GSK's earlier SiranBio deal, and Roche says it wants to be a top-three obesity player, so this is portfolio-building on the cheap: small upfront, back-loaded milestones. It's also Roche's fifth deal with a Chinese drugmaker since late August, a sign that the best-priced early assets are still found there.

Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race ↗